Πτυχιακή Εργασία

Pancreatogastrostomy versus pancreatojejunostomy after pancreaticoduodenectomy : an up-to-date metaanalysis of randomized controlled trials Παγκρεατογαστρική έναντι παγκρεατονηστιδικής έπειτα από παγκρεατοδωδεκαδακτυλεκτομή : μεταανάλυση προοπτικών τυχαιοποιημένων μελετών

Περιβολιώτης Κωνσταντίνος

Λάρισα 2016

Pancreatogastrostomy versus pancreatojejunostomy after pancreaticoduodenectomy : an up-to-date metaanalysis of randomized controlled trials

INTRODUCTION

Rationale

Pancreatoduodenectomy (PD) is still the gold standard of treatment for patients with resectable benign and malignant lesions of the head of the pancreas and the periampullary region. Although, PD is considered a safe operative technique, with 30-days mortality rates in specialized, high volume centers currently estimated bellow $3\%^{12}$, complications, such as postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE) and postpancreatoduodenectomy haemorrhage (POPH), increase the overall morbidity to the rate of 45%, despite the application of enhanced recovery approaches after surgery ³.

Given the fact that the frequency of POPF, the most notorious postpancreatoduodenectomy complication, remains an high as 40%⁴, researchers have focused on factors that may influence this rate, with the pancreatoenteric anastomosis being one of them. The anastomosis between the pancreatic stump and the GI is regarded as prone to leakage, due to exposure of the suture line to pancreatic juice. The two most widely adopted postpancreaticoduodenectomy anastomotic techniques, are the

pancreatogastrostomy (PG) and the pancreatojejunostomy (PJ) which combined with anastomotic reinforcing techniques, such as glue and intra-ductal stenting, are designed to provide a sealed and stable pancreatoenteric junction. In current literature, a series of retrospective and prospective studies⁵⁻¹⁰ have compared PG and PJ with inconclusive results. Keck et al. ¹¹, in a large multicenter randomized controlled trial, reported no difference between the two techniques in terms of clinically significant POPF, which is in contrast with results from previous meta-analyses¹²⁻¹⁴, where it was suggested that PG was a safer and more effective method of reconstruction, with lower rates of POPF and other intra-abdominal complications and shorter length of hospital stay (LOS). *Objectives*

In light of these conflicting evidence, we conducted a meta-analysis, in order to provide an up-to-date comparison of PG and PJ after PD, for benign or malignant diseases of the head of the pancreas and the periampullary region , in terms of POPF and other postoperative complications .

METHODS

Study protocol

The conduction of this meta-analysis was completed according to the PRISMA¹⁵ guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. The present study was not registrated in any database.

Primary Endpoint

The primary endpoint of this study was the rate of overall postoperative pancreatic fistula. POPF was defined by ISGPF ¹⁶ as a drain output of any measurable volume of fluid on or after POD 3 with an amylase content >3 times the serum amylase activity. Classification to grade A, B and C is based on the impact of POPF to the overall clinical course. *Secondary Endpoints*

Secondary endpoints included clinically significant POPF (grade B/C), postoperative delayed gastric emptying (DGE)¹⁷, clinically significant DGE (grade B/C), postpancreatectomy haemorrhage (PPH)¹⁸, clinically significant PPH (grade B/C), biliary fistula, intra-abdominal fluid collection, overall morbidity, mortality, reoperation rate, wound infection, intraoperative blood transfusion, operative time and the length of hospital stay (LOS).

Eligibility criteria

Eligible trials were prospective human studies with a RCT design, comparing PG and PJ after PD for benign or malignant diseases of the head of the pancreas and the periampullary region, whose outcome data were reported in English and could be retrieved. Excluded studies included those not written in English, with no outcome of interest, with no comparing group, observational, no randomized and no human studies. Moreover studies reported in the form of editorials, letters, conference abstracts, expert opinion or duplicate studies were excluded.

Literature search

A systematic literature search in electronic databases (MEDLINE and Cochrane Central Register of Controlled Clinical Trials) was performed (search date : 20 July 2016) in order to identify the eligible RCTs.

In order to perform the literature search the following keywords were used :

- <u>MEDLINE</u>: (Pancreaticoduodenectomy OR Pancreatoduodenectomy OR Whipple OR "pancreatoduodenal resection" OR "pancreaticoduodenal resection" OR pancreaticojejunostomy OR pancreatojejunostomy OR "pancreaticoenteric anastomosis" OR "pancreatoenteric anastomosis" OR pancreaticogastrostomy OR pancreatogastrostomy OR "pancreatogastrostomy OR "pancreatogastrostomy" OR "pancreatogastrostomy OR "pancreatogastrostomy OR "panc
- <u>Cochrane Central Register of Controlled Clinical Trials (Wiley)</u>: (Pancreaticoduodenectomy OR Pancreatoduodenectomy OR Whipple OR "pancreatoduodenal resection" OR "pancreaticoduodenal resection" OR pancreaticojejunostomy OR

pancreatojejunostomy OR "pancreaticoenteric anastomosis" OR "pancreatoenteric anastomosis" OR

pancreaticogastrostomy OR pancreatogastrostomy OR "pancreaticogastric anastomosis" OR "pancreatogastric

anastomosis" OR "pancreaticojejunal anastomosis" OR "pancreatojejunal anastomosis")

Study selection and Data collection

After duplicate removal, titles and abstracts of the studies were screened according to eligibility criteria. The next step included the full text review of the articles in order to assess that they are consistent with the inclusion criteria.

All electronic database search, study selection, data extraction, and methological assessment of the studies were performed blindly and in duplicate by two independent investigators (PK and SE). Disagreements were resolved by mutual revision and discussion, in order to reach a consensus. In case of not resolving the discrepancies, the opinion of a third investigator (TA) was considered. From all eligible studies the data extracted included : author's name, study location and year, RCT type, sample size, the age and gender of the participants, primary outcome, follow up duration, overall morbidity, underlying disease, operation type, rate of PD/pylorus preserving PD (PPPD), anastomotic technique, operative time, postoperative hospital stay, use of intraductal stent, glue and drains, postoperative administration of somatostatin, and information regarding the diameter of pancreatic duct and the texture of pancreas. Only results reported in the article of the studies were extracted.

All studies imported in this meta-analysis were submitted to rigorous quality and methodological evaluation for bias appraisal according to Cochrane's risk of bias assessing tool¹⁹. Validity checkpoints included assessment of random sequence allocation, allocation concealment, blinding of participants and personnel and blinding of outcome assessment, incomplete outcome data and selective reporting. Cohen's k statistic was also calculated.

Statistical Analysis

Data analysis was performed using the Cochrane Collaboration RevMan version 5.3 .Dichotomous variables were reported in the form of Odds Ratio (OR), while for continuous variables Weighted Mean Differences (WMD) were used. Results of the analyses were presented with the corresponding 95% Confidence Interval (95% CI).

In the case of continuous variables, if the article did not provide the mean and the Standard Deviation (SD), these were calculated from the median and the Interquartile Range (IR), based on the formula by Hojo et al²⁰. More specific, if the sample size was >25, then the mean was considered equal to the median. For sample sizes <70 ,SD was regarded as IR/4. If the sample size was >70, then SD was equal to IR/6. For dichotomous variables, the statistical method used was the Mantel-Haenszel (MH) and for continuous variables the Inverse Variance (IV). Both Fixed Effects (FE) and Random Effects (RE) model were calculated. The decision of which model to finally estimate was based on the Cochran Q test. If statistically significant heterogeneity was present (Q test P<0.1) then RE model was applied . Moreover heterogeneity was quantified with the use of I². The studies were weighted on the basis of sample size. Statistical significance was considered at the level of P<0.05.

Risk of bias across studies

The funnel plot of the primary outcome was also visually inspected, in order to determine the possible presence of publication bias. An Egger's test was also performed for the primary outcome.

RESULTS

Study selection

From the literature search, 1240 citations (Figure 1) were retrieved, published up to 20 July 2016. After the removing of 236 duplicate records, the screening of the titles and the abstracts begun. From the 1004 studies submitted to the first phase of the screening, 993 were excluded. More specific, 10 were comments or conference abstracts, 5 did not have a RCT design, 5 did not have a comparison group, 18 were reviews of the current literature, 20 were meta-analysis, 3 articles were not written in English, 23 compared different techniques of PG or PJ instead and 909 were irrelevant to the subject records. In full text review were submitted 11 articles ^{9 11 21-29}. At this step, 1 trial ⁹ was rejected due to, a no RCT design. Finally 10 studies ^{11 21-29} were included in qualitative analysis.

Study characteristics

Table 1 summarizes the characteristics of the included studies. The publication date ranges between 1995 up to 2016. Four studies were multi-centered while the other six were single-centered. Fernández-Cruz et al. ²⁴ was the first to adopt the ISGPS definition and classification of POPF. Since then, heterogeneity existed in the definition and diagnosis of POPF. The overall amount of patients included in this meta-analysis is 1629 (Table 2). A total of 826 PGs and 803 PJs were performed . The age of the participants extended from 12 to 87 years . Regarding the gender allocation between the two comparison groups, data are shown in Table 2. El Nakeeb et al. ²³ compared the results of PG and an isolated Roux loop pancreatojejunostomy while Fernández-Cruz et al. ²⁴, respectively compared PJ and PG with gastric partition. In the rest of the studies, PG was considered the intervention and PJ the control. All studies, except Duffas et al. ²² had the rate of POPF as primary outcome. Four studies ²¹²⁴²⁶²⁹ did not report the duration of follow up. In the other six studies follow up varied from 30 days to 12 months. Regarding the underlying disease, carcinoma of the pancreatic head was the most frequent (Table 3). The PD and PPPD ratio is shown in Table 3. There was a lack of uniformity between the studies regarding the technique of PG and PJ anastomoses. Both PG and PJ could be performed either in a telescoped or a duct-to mucosa manner. Table 4 reports a summary of the studies implementing the use of stents in the pancreatic duct, anastomotic glue reinforcement , and the overall drain use. Postoperative octreotide was administered in 7 studies ^{21-23 25-28}. All studies reported data regarding the main pancreatic duct diameter . Similarly, only Topal et al. ²⁷ did not provide the allocation of the patients regarding pancreatic texture.

Risk of bias within studies

Figure 2 represents a summary of the included studies quality assessment. More specifically, as shown in Figure 3, all studies included a random sequence generation procedure in their protocol. Allocation concealment was also applied in all studies except one ²⁹. Only two trials ^{11 22} reported the blinding of participants and personnel and the blinding of outcome assessment. Only in the study of Grendar et al. ²⁶ incomplete outcome data and possible selective reporting was detected. There was almost perfect agreement between the two investigators (Cohen's k statistic : 82.3% p<0.001) *Primary Endpoint*

All the included studies (Figure 4) provided comparison between the two anastomotic techniques regarding POPF. In summary, 138 patients from a total of 826 submitted to PG developed POPF, instead of 175 and 803 respectively in the PJ group. Meta-analysis of these data showed a statistically significant (p=0.008) lower ratio of POPF (OR:0.71, 95%CI: 0.55)

- 0.91) for the PG group. Since there was no significant heterogeneity between the studies (Q test P:0.27, I^2 :19%(95%CI : 0-59.8%)), a FE model was applied.

Secondary Endpoints

- All ten studies (Figure 6) compared the two anastomotic techniques regarding the clinically significant POPF. More specifically 108 patients from a total of 826 in the PG group developed clinically significant POPF, whereas in the PJ group the same ratio was 144/803. Meta-analysis of these data showed no statistically significant (p=0.09) difference between the two groups regarding clinically significant POPF (OR:0.70, 95%CI : 0.46 1.06). Since there was significant heterogeneity between the studies (Q test P:0.04, I² :48% (95%CI : 0-75%)), a RE model was applied.
- Eight studies (Figure 7) provided data for DGE. Meta-analysis of the data showed no statistically significant (p=0.75) difference between the two groups regarding DGE (OR:1.08, 95%CI : 0.68 1.70). Heterogeneity was significant between the studies (Q test P:0.04, I² :53%(95%CI : 0-78.9%)), so a RE model was used.
- Eight studies (Figure 8) provided data for clinically significant DGE. Meta-analysis of the data showed no statistically significant (p=0.93) difference between the two groups regarding clinically significant DGE (OR:0.98, 95%CI : 0.59 1.63). Heterogeneity was significant between the studies (Q test P:0.03, I² :55%(95%CI : 1.7%-79.8%)), so a random effects model was used.
- Eight studies (Figure 9) provided data for PPH. Meta-analysis of the data showed statistically significant (p=0.02) difference between the two groups regarding POPH (OR:1.52, 95% CI : 1.08 2.14) in favor of PJ group. Heterogeneity was not significant between the studies (Q test P:0.85, I² :0%(95% CI : 0-80.3%)), so a FE model was used.
- Eight studies (Figure 10) provided data for clinically significant PPH. Meta-analysis of the data showed no statistically significant (p=0.10) difference between the two groups regarding clinically significant POPH (OR:1.35, 95%CI: 0.95 1.93). Heterogeneity was not significant between the studies (Q test P:0.96, I²:0%(95%CI: 0-75.9%)), so a FE model was used.
- Seven studies (Figure 11) provided data for biliary fistula. Meta-analysis of the data showed no statistically significant (p=0.08) difference between the two groups regarding biliary fistula (OR:0.58, 95%CI : 0.31 1.06). Heterogeneity was not significant between the studies (Q test P:0.14, I² :38%(95%CI : 0-73.7%)), so a FE model was used.
- Nine studies (Figure 12) provided data for intra-abdominal fluid collection. Meta-analysis of the data showed no statistically significant (p=0.06) difference between the two groups regarding intra-abdominal fluid collection (OR:0.64, 95%CI : 0.40 1.02). Heterogeneity was significant between the studies (Q test P:0.07, I²:45%(95%CI : 0-74.6%)), so a RE model was used.
- Eight studies (Figure 13) provided data for morbidity. Meta-analysis of the data showed no statistically significant (p=0.82) difference between the two groups regarding morbidity (OR:0.97, 95%CI : 0.77 − 1.23). Heterogeneity was not significant between the studies (Q test P:0.21, I² :28% (95%CI : 0-67.5%)), so a FE model was used.
- Ten studies (Figure 14) provided data for mortality. Meta-analysis of the data showed no statistically significant (p=0.94) difference between the two groups regarding mortality (OR:0.98, 95% CI : 0.60 1.61). Heterogeneity was not significant between the studies (Q test P:0.94, I² :0%(95% CI : 0-76.8%)), so a FE model was used.
- Eight studies (Figure 15) provided data for reoperation rate. Meta-analysis of the data showed no statistically significant (p=0.33) difference between the two groups regarding reoperation rate (OR:0.84, 95% CI : 0.59 1.20). Heterogeneity was not significant between the studies (Q test P:0.79, I² :0%(95% CI : 0-83%)), so a FE model was used.
- Four studies (Figure 16) provided data for wound infection. Meta-analysis of the data showed no statistically significant (p=0.77) difference between the two groups regarding wound infection (OR:1.08, 95%CI : 0.66–1.76). Heterogeneity was not significant between the studies (Q test P:0.86, I² :0%(95%CI : 0-90%)), so a FE model was used.
- Six studies (Figure 17) provided data for blood transfusion. Meta-analysis of the data showed no statistically significant (p=0.86) difference between the two groups regarding blood transfusion (OR:1.03, 95%CI: 0.72 1.47). Heterogeneity was not significant between the studies (Q test P:0.39, I²:5%(95%CI: 0-91.4%)), so a FE model was used.
- Ten studies (Figure 18) provided data for operative time. Meta-analysis of the data showed no statistically significant (p=0.41) difference between the two groups regarding operative time (MWD:-5.73, 95%CI : -19.3, 7.85). Heterogeneity was significant between the studies (Q test P:<0.001, I² :97%(95%CI : 0-98.1%)), so a RE model was used.
- Ten studies (Figure 19) provided data for LOS. Meta-analysis of the data showed no statistically significant (p=0.33) difference between the two groups LOS (MWD:-0.74, 95%CI : -2.24, 0.76). Heterogeneity was significant between the studies (Q test P:<0.001, I² :91%(95%CI : 0-94.6%)), so a RE model was used.

Risk of bias across studies

Funnel plot of primary outcome (POPF) is shown in Figure 5. No study resides beyond the limits of 95% CI . Egger's test showed that there was no statistically significant publication bias (p=0.976).

DISCUSSION

Summary of evidence

Pancreaticoduodenectomy remains the most widely used surgical modality for the treatment of pancreatic head and periampullary tumors. Failure of the pancreatic anastomosis resulting in POPF has been identified as one of the most important factor of postoperative morbidity. It must also be mentioned that POPF is assumed to have a close relationship with other post PD complications, such as IAC, DGE and PPH³⁰³¹. As a result, surgeons, in an attempt to minimize post PD complications have meticulously compared the available anastomotic techniques.

In our study, after a systematic literature search, a meta-analysis of available RCTs was performed. In the qualitative and quantitative analysis, 10 studies with a total of 1629 patients were included. Regarding the primary outcome, PG was superior to PJ, thus, presenting lower rates of overall POPF. However this result was not confirmed when the two techniques were compared on the basis of clinically significant POPF, where no statistically significant difference was found. Heterogeneity in clinically significant POPF could possibly be the result of non uniformity in the definition of POPF. Although the included studies after 2005 were consistent with the 2005 ISGPS POPF definition, the remaining , defined POPF in an inconsistent way. DGE and clinically

significant DGE were found to have no difference between PG and PJ, with a high level of heterogeneity though. As the operation type was not determined in most eligible studies, surgeons performed either PD or PPPD. The above mentioned heterogeneity could be explained in the light of lack of stratification regarding the operation type. Respectively, results from pooled data showed a lower rate of PPH for PJ, but no difference for clinically significant PPH. Heterogeneity for both of them was 0%, increasing thus the validity of these findings. The rate of biliary fistula and the intra abdominal fluid collection was not significantly different between PG and PJ, which diverges from the results of previous studies³²⁻³⁵, due to inclusion of the recent RCTs ^{11 26}. Moreover, overall postoperative morbidity for both techniques was estimated at the level of 49%, complying with current literature ⁴. Similarly, no difference was found in terms of mortality, reoperation rate, wound infection and perioperative blood transfusion. Finally, PG was not superior to PJ in terms of operation time and LOS. Heterogeneity was significantly high in these comparisons, possibly due to the approximate calculation of the mean and SD.

It is common knowledge between surgeons, that risk factors for development of POPF are the age, gender of the patient, preoperative jaundice and malnutrition, underlying pathology, pancreatic texture and pancreatic duct size, operative time, resection type, anastomotic technique, and intraoperative blood loss ³⁶. El Nakeeb et al.³¹, however, in a retrospective study of 471 patients, suggested that risk factors for POPF include the cirrhotic liver, BMI, soft pancreas, pancreatic diameter <3mm, and pancreatic duct near the posterior border. This is inconsistent with the results from our meta-analysis, were PG was proven superior to PJ for overall POPF, mainly due to the imbalance of the two groups (PG: 424, PJ:46) in the above mentioned study.

The superiority of PG over PJ in terms of POPF can be justified by some theoretical advantages. Firstly, due to the fact that the posterior wall of the stomach lies just above the pancreatic remnant, the tension between the stomach and the pancreatic stump is minimized. Secondly, the acidic gastric content prevent the activation of pancreatic enzymes and consequently the the anastomotic lysis. Moreover, compared to a jejunum loop, the stomach wall is thicker, thus stabilizing the anastomosis. Finally, the abundant stomach wall vascularization, decreases the chance of an anstomotic ischaemia. This may also be the reason of increased post PD PPH in the PG group, rendering perioperative meticulous haemostasis of utmost importance.

As far as postoperative endocrine and exocrine pancreatic function is concerned, data are scarce and inconsistent, thus making further analysis very difficult . Figueras et al. ²⁵ reported a higher stool elastase level and significant lesser weight loss in the PG group. Comparing PG and IRPJ, El Nakeeb et al. ²³, concluded that postoperative steatorrhea and need for pancreatic enzyme supplements was higher in the PG group, while post PD serum albumin was in a lower level in patients submitted to PG. In the most recent RCT, Keck et al. ¹¹ found that the need for oral enzyme supplements in six months after surgery was lower in the PG group, with the rate of reported steatorrhea further decreasing after 12 months.

Our meta-analysis provides an up-to-date pooled, published only data, estimation of the rate of POPF and other postoperative complications between the two most popular anastomotic technique. Compared to other recent studies ^{12 37}, it reports results not only in overall morbidity, but also in clinically significant complications, such as DGE and PPH.

Limitations Several limitations

Several limitations should be taken into account before appraising the results of this meta-analysis. First of all, there is a diversity in the POPF definition among the included studies. It must be noted, though, that all studies after 2005 use the ISGPS definition. The included trials have also incorporotated, both PD and PPPD in their study groups and there was ,also, no stratification on the basis of the underlying pathology. Moreover, a lack of uniformity exists, regarding the surgical anastomotic technique that may possibly result in biased results. Factors, like the texture of pancreas and the pancreatic duct diameter might also influence the results. Another source of bias could be the perioperative use of glue and stents and the postoperative administration of somatostatin ,since not all studies reported these information. Finally, another factor that contributes in heterogeneity is the surgical experience in the applied anastomotic technique.

Conclusions

The present meta-analysis of RCTs, demonstrates that, PG has lower overall incidence of POPF and higher rate of PPH against PJ. There was no difference between the two anastomotic techniques regarding clinically significant POPF, DGE, clinically significant DGE, clinically significant PPH, bilary fistula, intra-abdominal fluid collection, overall morbidity, mortality, reoperation rate, wound infection, intraoperative blood transfusion, operative time and LOS. Given several limitations, more large scale high quality RCTs are required for the effect of the anastomotic technique on the incidence of POPF to be clarified.

FUNDING

There was no financial support for the accomplishment of this study. **REFERENCES**

- 1. Lidsky ME, Sun Z, Nussbaum DP, et al. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Annals of surgery 2016.
- 2. Gleeson EM, Shaikh MF, Shewokis PA, et al. WHipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database. Surgery 2016.
- 3. Xiong J, Szatmary P, Huang W, et al. Enhanced Recovery After Surgery Program in Patients Undergoing Pancreaticoduodenectom y: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine 2016;95(18):e3497.
- 4. Conzo G, Gambardella C, Tartaglia E, et al. Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review. International journal of surgery (London, England) 2015;21 Suppl 1:S4-9.
- 5. Abou Khalil J, Mayo N, Dumitra S, et al. Pancreatic fistulae after a pancreatico-duodenectomy: are pancreatico-gastrostomies safer than pancreatico-jejunostomies? An expertise-based trial and propensity-score adjusted analysis. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014;16(12):1062-7.
- 6. Arnaud JP, Tuech JJ, Cervi C, et al. Pancreaticogastrostomy compared with pancreaticojejunostomy after pancreaticoduodenectomy. The European journal of surgery = Acta chirurgica 1999;165(4):357-62.
- Heeger K, Fendrich V, Waldmann J, et al. Reduced complication rate after modified binding purse-string-mattress sutures pancreatogastrostomy versus duct-to-mucosa pancreaticojejunostomy. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2013;11(5):246-52.
- Oussoultzoglou E, Bachellier P, Bigourdan JM, et al. Pancreaticogastrostomy decreased relaparotomy caused by pancreatic fistula after pancreaticoduodenectomy compared with pancreaticojejunostomy. Archives of surgery (Chicago, Ill : 1960) 2004;139(3):327-35.
- 9. Takano S, Ito Y, Watanabe Y, et al. Pancreaticojejunostomy versus pancreaticogastrostomy in reconstruction following pancreaticoduodenectomy. The British journal of surgery 2000;87(4):423-7.

- Tuech JJ, Pessaux P, Duplessis R, et al. [Pancreatojejunal or pancreatogastric anastomosis after cephalic duodenopancreatectomy. A comparative retrospective study]. Chirurgie; memoires de l'Academie de chirurgie 1998;123(5):450-5.
- Keck T, Wellner UF, Bahra M, et al. Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767): Perioperative and Long-term Results of a Multicenter Randomized Controlled Trial. Annals of surgery 2016;263(3):440-9.
- 12. Guerrini GP, Soliani P, D'Amico G, et al. Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy: An Up-todate Meta-Analysis. Journal of investigative surgery : the official journal of the Academy of Surgical Research 2016;29(3):175-84.
- 13. Liu FB, Chen JM, Geng W, et al. Pancreaticogastrostomy is associated with significantly less pancreatic fistula than pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: a meta-analysis of seven randomized controlled trials. HPB : the official journal of the International Hepato Pancreato Biliary Association 2015;17(2):123-30.
- 14. Que W, Fang H, Yan B, et al. Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. American journal of surgery 2015;209(6):1074-82.
- 15. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009;6(7):e1000097.
- 16. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138(1):8-13.
- 17. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142(5):761-8.
- Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142(1):20-5.
- 19. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2011;343:d5928.
- 20. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005;5:13.
- 21. Bassi C, Falconi M, Molinari E, et al. Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. Annals of surgery 2005;242(6):767-71, discussion 71-3.
- 22. Duffas JP, Suc B, Msika S, et al. A controlled randomized multicenter trial of pancreatogastrostomy or pancreatojejunostomy after pancreatoduodenectomy. American journal of surgery 2005;189(6):720-9.
- 23. El Nakeeb A, Hamdy E, Sultan AM, et al. Isolated Roux loop pancreaticojejunostomy versus pancreaticogastrostomy after pancreaticoduodenectomy: a prospective randomized study. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014;16(8):713-22.
- 24. Fernandez-Cruz L, Cosa R, Blanco L, et al. Pancreatogastrostomy with gastric partition after pylorus-preserving pancreatoduodenectomy versus conventional pancreatojejunostomy: a prospective randomized study. Annals of surgery 2008;248(6):930-8.
- 25. Figueras J, Sabater L, Planellas P, et al. Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy. The British journal of surgery 2013;100(12):1597-605.
- 26. Grendar J, Ouellet JF, Sutherland FR, et al. In search of the best reconstructive technique after pancreaticoduodenectomy: pancreaticojejunostomy versus pancreaticogastrostomy. Canadian journal of surgery Journal canadien de chirurgie 2015;58(3):154-9.
- 27. Topal B, Fieuws S, Aerts R, et al. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticod uodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. The Lancet Oncology 2013;14(7):655-62.
- 28. Wellner UF, Sick O, Olschewski M, et al. Randomized controlled single-center trial comparing pancreatogastrostomy versus pancreaticojejunostomy after partial pancreatoduodenectomy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16(9):1686-95.
- 29. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Annals of surgery 1995;222(4):580-8; discussion 88-92.
- 30. Topal B, Aerts R, Hendrickx T, et al. Determinants of complications in pancreaticoduodenectomy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007;33(4):488-92.
- 31. El Nakeeb A, Salah T, Sultan A, et al. Pancreatic anastomotic leakage after pancreaticoduodenectomy. Risk factors, clinical predictors, and management (single center experience). World journal of surgery 2013;37(6):1405-18.
- 32. Lei P, Fang J, Huang Y, et al. Pancreaticogastrostomy or pancreaticojejunostomy? Methods of digestive continuity reconstruction after pancreaticodudenectomy: a meta-analysis of randomized controlled trials. International journal of surgery (London, England) 2014;12(12):1444-9.
- 33. Menahem B, Guittet L, Mulliri A, et al. Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Annals of surgery 2015;261(5):882-7.
- 34. Xiong JJ, Tan CL, Szatmary P, et al. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. The British journal of surgery 2014;101(10):1196-208.
- 35. Zhou Y, Yu J, Wu L, et al. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy on occurrences of postoperative pancreatic fistula after pancreaticoduodenectomy. Asian journal of surgery / Asian Surgical Association 2015;38(3):155-60.
- Machado NO. Pancreatic fistula after pancreatectomy: definitions, risk factors, preventive measures, and management-review. International journal of surgical oncology 2012;2012:602478.
- 37. Crippa S, Cirocchi R, Randolph J, et al. Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 2016;401(4):427-37.

APPENDIX Tables

Indies					
PMID	First author	Country	Publication year	RCT type	POPF definition
26135690	Keck	GERMANY	2016	multicenter ,randomized, controlled, observer- and patient- blinded trial	ISGPS (grade B/C)
25799130	Grendar	CANADA	2015	single-center randomized controlled trial	Radiologically proven anastomotic leak or

					continued drainage of lipase-rich fluid on PoD 10. Classification by ISGPS
24467711	El Nakeeb	EGYPT	2014	single center, prospective randomized study	ISGPS (grades A/B/C)
24264781	Figueras	SPAIN	2013	multicenter, prospective randomized study	ISGPS(grade B/C)
23643139	Topal	BELGIUM	2013	multicentre, randomised superiority trial	ISGPS(grade B/C)
22744638	Wellner	GERMANY	2012	single center, open, randomized controlled study	ISGPS(grade B/C)
19092337	Fernández- Cruz	SPAIN	2008	single center ,prospective randomized study	ISGPS(grade B/C)
16327486	Bassi	ITALY	2005	single center ,prospective and randomized study	Any clinical significant output of fluid, rich in amylase, confirmed by fistulography
15910726	Duffas	FRANCE	2005	multicenter, single blind, controlled randomized, trial	Fluid obtained through drains or percutaneous aspiration, containing at least 4 times normal serum values of amylase for 3 days or as anastomotic leaks shown by fistulography
7574936	Yeo	USA	1995	single center , prospective randomized trial	Drainage of greater than 50 mL of amylase rich fluid (greater than threefold elevation above upper limit of normal in serum) through the operatively placed drains on or after

Table 1. Included studies

First author	Sam size	ple	Age		Gender	r (M/F)	Intervention	Comparator	Primary outcome	Follow up	Mort	oidity
	PG	PJ	PG	PJ	PG	РJ					PG	PJ
Keck	17 1	14 9	68(35 -86)	66(29- 87)	95/76	93/5 6	PG	РJ	clinically relevant POPF,gra de B or C	12 months	N/A	
Grendar	48	50	63.6±13.1	68. 1 ± 10. 7	20/28	29/2 1	PG	PJ	rate of pancreati c anastomo tic leak/fistul a	N/A	29	24
El Nakeeb	45	45	58 (12– 73)	54 (15 - 73)	23/22	27/1 8	PG	isolated Roux loop pancreaticoje junostomy	rate of POPF	12 months	17	14
Figueras	65	58	67 (35– 80)	65. 5 (42 - 80)	44/21	37/2 1	PG	PJ	rate of POPF	6 months	41	38
Topal	16 2	16 7	67.0 (60.6– 73.5)	66. 1 (59. 4– 74. 6)	100/6 2	91/7 6	PG	PJ	clinically relevant POPF,gra de B or C	2 months	100	99
Wellner	59	57	67 (34–	64 (23	27/32	29/2 8	PG	PJ	clinically relevant	90 days	N/A	

			84)	_					POPF,gra			
				81)					de B or C			
Fernández	53	55	$63 \pm$	63	29/24	38/1	PG with	PJ	rate of	N/A	12	24
-Cruz			13	±		7	gastric		POPF			
				14			partition					
Bassi	69	82	59.3	55.	44/25	35/3	PG	PJ	rate of	N/A	20	32
			(58.2–	5(5		3			POPF			
			60.4)	4.5								
				_								
				56.								
				6)								
Duffas	81	68	$58.2 \pm$	58.	51/30	35/3	PG	PJ	rate of	30 days	37	32
			11	$6 \pm$		3			one or			
				12					more			
									postopera			
									tive IACs			
Yeo	73	72	$61.5 \pm$	62.	33/40	38/3	PG	PJ	rate of	N/A	36	31
			1.7	$4 \pm$		4			POPF			
				1.4								

Table 2. Study characteristics

First author	Disease (PDAC MP/DB HER	/DD/A	Opera tion type	pd/p	ppd	Technique		Operativ	ve time	Postope hospital	
	PG	PJ		PG	PJ	PG	PJ	PG	PJ	PG	PJ
Keck	104/- /10/- /14	98/- /11/- /14	pd or pppd	37/ 134	28/ 12 1	dunking, pursestring or interrupted or combination suture	duct to mucosa or dunking, running or interrupted or combination suture	332(16 5–600)	337(16 5–565)	15(5– 208)	16(3– 129)
Grendar	N/A		pd or pppd	N/A		posterior gastrostomy,2 layers anastomosis	2-layer end-to- side anastomosis	349 ± 70	356 ± 65	17.4± 11.6	14.0± 5.4
El Nakeeb	26/2/1 7/0/0	20/4/ 19/2/ 0	pd	45/ 0	45/ 0	posterior gastrostomy,2 layers anastomosis	two layers end- to-side pancreaticojejun ostomy	300 (210– 420)	320 (240– 480)	9 (4– 34)	8 (5– 41)
Figueras	33/6/8 /8/10	29/10 /7/3/1 9	pd or pppd	35/ 30	30/ 28	posterior gastrostomy double-layer invaginated	duct-to-mucosa pancreaticojejun ostomy	330 (235– 620)	305 (240– 510)	12 (1– 52)	15,5 (6–55)
Topal	98/11/ 23/28/ 2	107/1 4/28/ 15/3	pd or pppd	65/ 98	65/ 10 2	end-to-side telescoped antecolic posterior gastrostomy	end-to-side telescoped pancreaticojejun ostomy	250 (210– 320)	250 (210– 310)	19 (14– 25)	18 (14– 25)
Wellner	26/3/9 /2/8	30/2/ 7/2/1 0	pd or pppd	7/5 2	2/5 5	invagination, posterior pancreatogastros tomy with pursestring suture	duct-to mucosa pancreaticojejun ostomy	404 (280– 629)	443 (230– 683)	15 (7– 135)	17 (10– 60)
Fernánde z-Cruz	26/1/1 2/8/9	28/1/ 10/7/ 9	pppd	0/5 3	0/5 5	End-to-side duct- to- mucosa pancreatogastros tomy	end-to-side duct mucosa anastomosis PPPD-PJ	300 ± 50	310 ± 60	12 ±2	16 ± 3
Bassi	32/1/1 3/1/22	28/1/ 11/2/ 40	pd or pppd	3/6 6	12/ 70	posterior single layer telescoped gastrostomy	single-layer pancreaticojejun al or duct to mucosa	337.2 (336.1– 338.2)	359.3 (352.9– 354.9)	14.2 (13.1– 15.3)	15.4 (14.3– 16.5)
Duffas	34/3/1 7/8/19	25/3/ 19/11 /10	pd or pppd	63/ 18	50/ 18	depending surgeon's preference	depending surgeon's preference	6.5 ± 2.6 (h)	6.4 ± 2.2 (h)	20 (1– 98)	21 (7– 97)
Yeo	40/4/7	40/5/	pd or	13/	13/	posterior	end -to- end or	7.4 ±	7.2 ±	17.1 ±	17.7 ±


ſ	/6	/16	11/7/	pppd	60	59	gastrostomy	end-to-side	0.2(h)	0.2(h)	1.6	1.5
			9					pancreaticojejun				
								ostomy				

Table 3. Operative characteristics

First author	Stent		Postop octreot		Anastor glue reinforc		Drains	5	Pancrea parencl (soft/ha	nyma	Pancreati diameter	c duct
	PG	PJ	PG	PJ	PG	PJ	PG	PJ	PG	PJ	PG	PJ
Keck	N/A		N/A		N/A		N/A		95/66	83/62	94 (<3mm)	78
Grendar	10	39	42	39	N/A		38	44	25/23	18/32	3.8 ± 2.4 (mm)	4.3 ± 2.6
El Nakeeb	0	0	45	45	N/A		N/A		26/19	22/23	22 (<3mm)	21
Figueras	N/A		65	58	N/A		65	58	34/31	33/25	4 (1–15) (mm)	4 (1–11)
Topal	0	0	162	167	0	0	162	167	N/A		98 (<3mm)	102
Wellner	0	57	22	13	N/A		59	57	35/23	29/28	26 (<3mm)	18
Fernánde z-Cruz	53	55	0	0	N/A		53	55	24/29	25/30	3.0 ± 1.7 (mm)	3.0 ±1.6
Bassi	0	0	69	82	N/A		69	82	69/0	82/0	<5 mm	
Duffas	15	15	22	22	17	1 2	81	68	49/32	41/27	32 (<3mm)	31
Yeo	0	0	0	0	0	0	73	72	16/21	17/28	3.4 ± 0.2 (mm)	2.9 ± 0.2

Table 4. Intraoperative characteristics

Figures






Figure 2. Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.






Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	9	69	13	82	7.0%	0.80 [0.32, 1.99]	
Duffas et al.	13	81	14	68	8.7%	0.74 [0.32, 1.70]	
El Nakeeb et al.	10	45	9	45	4.8%	1.14 [0.41, 3.15]	
Fernández-Cruz et al.	2	53	10	55	6.4%	0.18 [0.04, 0.85]	-
Figueras et al.	10	65	20	58	12.2%	0.35 [0.15, 0.82]	
Grendar et al.	12	48	9	50	4.5%	1.52 [0.57, 4.02]	
Keck et al.	34	171	33	149	19.3%	0.87 [0.51, 1.50]	
Topal et al.	33	162	52	167	27.8%	0.57 [0.34, 0.94]	
Wellner et al.	6	59	7	57	4.4%	0.81 [0.25, 2.57]	
Yeo et al.	9	73	8	72	4.8%	1.13 [0.41, 3.10]	
Total (95% CI)		826		803	100.0%	0.71 [0.55, 0.91]	◆
Total events	138		175				
Heterogeneity: Chi ² = 1	1.12, df=	9 (P = I	0.27); I ² =	19%			
Test for overall effect: Z	•	•					0.01 0.1 1 10 100 Favours (PG) Favours (PJI)

Figure 4. Postoperative pancreatic fistula





	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bassi et al.	9	69	13	82	10.6%	0.80 [0.32, 1.99]	
Duffas et al.	13	81	11	68	11.1%	0.99 [0.41, 2.38]	
El Nakeeb et al.	7	45	4	45	6.9%	1.89 [0.51, 6.97]	
Fernández-Cruz et al.	2	53	10	55	5.3%	0.18 [0.04, 0.85]	
Figueras et al.	7	65	19	58	10.2%	0.25 [0.10, 0.65]	_
Grendar et al.	8	48	6	50	8.3%	1.47 [0.47, 4.59]	
Keck et al.	34	171	33	149	16.1%	0.87 [0.51, 1.50]	_ _
Topal et al.	13	162	33	167	13.8%	0.35 [0.18, 0.70]	
Wellner et al.	6	59	7	57	8.1%	0.81 [0.25, 2.57]	
Yeo et al.	9	73	8	72	9.5%	1.13 [0.41, 3.10]	
Total (95% CI)		826		803	100.0%	0.70 [0.46, 1.06]	•
Total events	108		144				_
Heterogeneity: Tau ² = 0	0.20; Chi ² ÷	= 17.40), df = 9 (F	P = 0.04	4); l ² = 489	%	
Test for overall effect: Z	•						0.01 0.1 1 10 100 Favours [PG] Favours [PJ]




Figure 6. Clinically significant postoperative pancreatic fistula

Figure 7. Delayed gastric emptying.

	PG		PJ			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Bassi et al.	2	69	10	82	7.5%	0.21 [0.05, 1.02]			
El Nakeeb et al.	9	45	4	45	9.8%	2.56 [0.73, 9.03]		- 	
Fernández-Cruz et al.	2	53	8	55	7.2%	0.23 [0.05, 1.14]			
Figueras et al.	9	65	11	58	13.0%	0.69 [0.26, 1.80]			
Keck et al.	20	171	21	149	17.3%	0.81 [0.42, 1.56]			
Topal et al.	25	162	13	167	16.5%	2.16 [1.06, 4.39]			
Wellner et al.	14	59	9	57	13.4%	1.66 [0.65, 4.21]		- +-	
Yeo et al.	16	73	16	72	15.4%	0.98 [0.45, 2.15]		-	
Total (95% CI)		697		685	100.0%	0.98 [0.59, 1.63]		•	
Total events	97		92						
Heterogeneity: Tau ² = 0	.28; Chi ^z :	= 15.73), df = 7 (F	P = 0.03	3); I² = 5 5'	%	L		- 100
Test for overall effect: Z	= 0.08 (P	= 0.93))				0.01	0.1 1 10 Favours (PG) Favours (PJ)	100

Figure 8. Clinically significant delayed gastric emptying.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	3	69	6	82	9.6%	0.58 [0.14, 2.39]	
Duffas et al.	13	81	9	68	15.0%	1.25 [0.50, 3.14]	_
El Nakeeb et al.	4	45	2	45	3.3%	2.10 [0.36, 12.08]	
Fernández-Cruz et al.	1	53	1	55	1.8%	1.04 [0.06, 17.04]	
Figueras et al.	13	65	7	58	10.8%	1.82 [0.67, 4.93]	
Keck et al.	36	171	17	149	26.2%	2.07 [1.11, 3.87]	
Topal et al.	21	162	17	167	26.6%	1.31 [0.67, 2.59]	- -
Wellner et al.	6	59	4	57	6.7%	1.50 [0.40, 5.62]	-
Total (95% CI)		705		681	100.0%	1.52 [1.08, 2.14]	◆
Total events	97		63				
Heterogeneity: Chi ² = 3	.40, df = 7	(P = 0.	.85); I ^z = ()%			
Test for overall effect: Z	.= 2.42 (P	= 0.02)				0.01 0.1 1 10 100 Favours [PG] Favours [PJ]

Figure 9. Postpancreatectomy haemorrhage.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	3	69	6	82	10.0%	0.58 [0.14, 2.39]]
Duffas et al.	13	81	9	68	15.7%	1.25 [0.50, 3.14]]
El Nakeeb et al.	4	45	2	45	3.5%	2.10 [0.36, 12.08]]
Fernández-Cruz et al.	1	53	1	55	1.8%	1.04 [0.06, 17.04]]
Figueras et al.	11	65	7	58	11.7%	1.48 [0.53, 4.12]]
Keck et al.	27	171	16	149	27.5%	1.56 [0.80, 3.02]] +
Topal et al.	21	162	17	167	27.8%	1.31 [0.67, 2.59]]
Wellner et al.	2	59	1	57	1.9%	1.96 [0.17, 22.29]]
Total (95% CI)		705		681	100.0%	1.35 [0.95, 1.93]	•
Total events Heterogeneity: Chi² = 1 Test for overall effect: Z	-	-)%			0.01 0.1 1 10 100 Favours [PG] Favours [PJ]

Figure 10. Clinically significant postpancreatectomy haemorrhage.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	0	69	7	82	24.1%	0.07 [0.00, 1.29]	← ■
Duffas et al.	6	81	2	68	7.1%	2.64 [0.52, 13.53]	
El Nakeeb et al.	6	45	4	45	12.3%	1.58 [0.41, 6.02]	
Fernández-Cruz et al.	0	53	1	55	5.2%	0.34 [0.01, 8.52]	
Figueras et al.	1	65	6	58	22.1%	0.14 [0.02, 1.16]	
Keck et al.	3	171	5	149	18.6%	0.51 [0.12, 2.19]	
Yeo et al.	1	73	3	72	10.6%	0.32 [0.03, 3.15]	
Total (95% CI)		557		529	100.0%	0.58 [0.31, 1.06]	•
Total events	17		28				
Heterogeneity: Chi ² = 9	.62, df = 6	i (P = 0.	14); I ² = 3	38%			
Test for overall effect: Z	:= 1.78 (P	= 0.08)				0.01 0.1 1 10 100 Favours (PG) Favours (PJ)

Figure 11. Biliary fistula.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Bassi et al.	7	69	22	82	13.1%	0.31 [0.12, 0.77]	_
Duffas et al.	11	81	16	68	14.2%	0.51 [0.22, 1.19]	
El Nakeeb et al.	6	45	4	45	8.3%	1.58 [0.41, 6.02]	
Fernández-Cruz et al.	2	53	8	55	6.4%	0.23 [0.05, 1.14]	
Figueras et al.	5	65	10	58	10.3%	0.40 [0.13, 1.25]	
Keck et al.	33	171	31	149	19.5%	0.91 [0.53, 1.58]	
Topal et al.	9	162	21	167	14.7%	0.41 [0.18, 0.92]	
Wellner et al.	7	59	3	57	7.8%	2.42 [0.59, 9.88]	
Yeo et al.	4	73	2	72	5.7%	2.03 [0.36, 11.44]	
Total (95% CI)		778		753	100.0%	0.64 [0.40, 1.02]	•
Total events	84		117				
Heterogeneity: Tau ² = 0	.21; Chi ≩∘	= 14.57	', df = 8 (F	P = 0.07	7); l² = 45'	%	
Test for overall effect: Z	= 1.86 (P	= 0.06))				0.01 0.1 1 10 100 Favours (PG) Favours (PJ)

Figure 12. Intra-abdominal fluid collection.

	PG PJ					Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	20	69	32	82	14.4%	0.64 [0.32, 1.26]	· -•+
Duffas et al.	37	81	32	68	13.1%	0.95 [0.50, 1.81]	
El Nakeeb et al.	17	45	14	45	6.1%	1.34 [0.56, 3.22]	<mark>- • − −</mark>
Fernández-Cruz et al.	12	53	24	55	12.7%	0.38 [0.16, 0.87]	
Figueras et al.	41	65	38	58	10.3%	0.90 [0.43, 1.88]	_
Grendar et al.	29	48	24	50	6.5%	1.65 [0.74, 3.69]	 • −
Topal et al.	100	162	99	167	25.9%	1.11 [0.71, 1.72]	│ — — — —
Yeo et al.	36	73	31	72	11.0%	1.29 [0.67, 2.48]	I − + −−
Total (95% CI)		596		597	100.0%	0.97 [0.77, 1.23]	↓
Total events	292		294				
Heterogeneity: Chi ² = 9	.68, df = 7	(P = 0.	21); I ^z = 2	28%			
Test for overall effect: Z	= 0.22 (P	= 0.82)				0.01 0.1 1 10 100 Favours (PG) Favours (PJ)

Figure 13. Morbidity.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	0	69	1	82	4.3%	0.39 [0.02, 9.75]	
Duffas et al.	10	81	7	68	21.2%	1.23 [0.44, 3.42]	
El Nakeeb et al.	4	45	3	45	8.7%	1.37 [0.29, 6.48]	
Fernández-Cruz et al.	0	53	0	55		Not estimable	
Figueras et al.	3	65	3	58	9.6%	0.89 [0.17, 4.58]	
Grendar et al.	2	48	1	50	3.0%	2.13 [0.19, 24.30]	
Keck et al.	10	169	8	148	25.5%	1.10 [0.42, 2.87]	
Topal et al.	4	162	8	167	24.4%	0.50 [0.15, 1.70]	
Wellner et al.	1	59	1	57	3.2%	0.97 [0.06, 15.81]	
Yeo et al.	0	73	0	72		Not estimable	
Total (95% CI)		824		802	100.0%	0.98 [0.60, 1.61]	◆
Total events	34		32				
Heterogeneity: Chi ² = 2	.28, df = 7	(P = 0.	.94); I ² = ()%			
Test for overall effect: Z	•	•					0.01 0.1 1 10 100 Favours [PG] Favours [PJ]

Figure 14. Mortality.

	PG		РJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Bassi et al.	5	69	5	82	6.5%	1.20 [0.33, 4.34]	
Duffas et al.	15	81	15	68	20.3%	0.80 [0.36, 1.79]	
El Nakeeb et al.	4	45	3	45	4.2%	1.37 [0.29, 6.48]	
Fernández-Cruz et al.	1	53	1	55	1.5%	1.04 [0.06, 17.04]	
Keck et al.	20	171	27	149	38.9%	0.60 [0.32, 1.12]	
Topal et al.	14	162	17	167	23.3%	0.83 [0.40, 1.75]	
Wellner et al.	7	59	4	57	5.5%	1.78 [0.49, 6.46]	
Yeo et al.	0	73	0	72		Not estimable	
Total (95% CI)		713		695	100.0%	0.84 [0.59, 1.20]	•
Total events	66		72				
Heterogeneity: Chi ^z = 3	.15, df = 6	(P = 0.	.79); I ^z = ()%			
Test for overall effect: Z	= 0.97 (P	= 0.33)				0.01 0.1 1 10 100 Favours [PG] Favours [PJ]

Figure 15. Reoperation.

	PG		PJ			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
El Nakeeb et al.	2	45	3	45	9.4%	0.65 [0.10, 4.10]	· · · · · · · · · · · · · · · · · · ·
Fernández-Cruz et al.	3	53	2	55	6.0%	1.59 [0.25, 9.92]	
Keck et al.	20	171	18	149	55.4%	0.96 [0.49, 1.90]	_
Yeo et al.	14	73	11	72	29.2%	1.32 [0.55, 3.13]	
Total (95% CI)		342		321	100.0%	1.08 [0.66, 1.76]	↓ ◆
Total events	39		34				
Heterogeneity: Chi ² = 0	.77, df = 3	(P = 0)					
Test for overall effect: Z	= 0.29 (P	= 0.77	0.01 0.1 1 10 100 Favours (PG) Favours (PJ)				

Figure 16. Wound Infection.

	PG		PJ			Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Bassi et al.	5	69	5	82	7.0%	1.20 [0.33, 4.34]		
Duffas et al.	19	81	12	68	16.6%	1.43 [0.64, 3.21]		- +•
Fernández-Cruz et al.	15	53	16	55	18.7%	0.96 [0.42, 2.22]		
Grendar et al.	5	48	13	50	19.0%	0.33 [0.11, 1.02]		
Keck et al.	25	171	17	149	25.8%	1.33 [0.69, 2.57]		
Wellner et al.	9	59	9	57	12.9%	0.96 [0.35, 2.62]		
Total (95% CI)		481		461	100.0%	1.03 [0.72, 1.47]		. ◆
Total events	78		72					
Heterogeneity: Chi ² = 5	.25, df = 5	(P = 0.	.39); I ² = 5	5%				0.1 1 10 100
Test for overall effect: Z	= 0.17 (P	= 0.86))				0.01	0.1 1 10 100 Favours (PG) Favours (PJ)

Figure 17. Blood transfusion.

		PG			PJ			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	I IV, Random, 95% CI
Bassi et al.	337.2	4.23	69	359.3	4.61	82	13.3%	-22.10 [-23.51, -20.69]] •
Duffas et al.	390	156	81	384	132	68	5.2%	6.00 [-40.24, 52.24]]
El Nakeeb et al.	300	52.5	45	320	60	45	9.6%	-20.00 [-43.29, 3.29]]
Fernández-Cruz et al.	300	50	53	310	60	55	10.2%	-10.00 [-30.80, 10.80]]
Figueras et al.	330	96.25	65	305	67.5	58	8.3%	25.00 [-4.14, 54.14]] +
Grendar et al.	349	70	48	356	65	50	8.8%	-7.00 [-33.77, 19.77]	j
Keck et al.	332	72.5	171	337	66.6	149	11.4%	-5.00 [-20.25, 10.25]]
Topal et al.	250	18.3	162	250	16.6	167	13.2%	0.00 [-3.78, 3.78]	1 +
Wellner et al.	404	87.25	59	443	113.25	57	6.7%	-39.00 [-75.88, -2.12]]
Yeo et al.	444	12	73	432	12	72	13.2%	12.00 [8.09, 15.91]] –
Total (95% CI)			826			803	100.0%	-5.73 [-19.30, 7.85]	1 🔶
Heterogeneity: Tau ² = 3	359.13; C	; hi² = 35	50.82, c	lf = 9 (P	< 0.0000	1); I ² =	97%		
Test for overall effect: Z									-100 -50 Ó 50 10 Favours (PG) Favours (PJ)

Figure 18. Operative time.

		PG			РJ			Mean Difference		Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% Cl		
Bassi et al.	14.2	4.65	69	15.4	5.07	82	14.5%	-1.20 [-2.75, 0.35]		•		_
Duffas et al.	20	16.16	81	21	22.5	68	4.2%	-1.00 [-7.40, 5.40]		-		
El Nakeeb et al.	9	7.5	45	8	9	45	9.1%	1.00 [-2.42, 4.42]		+		
Fernández-Cruz et al.	12	2	53	16	3	55	16.0%	-4.00 [-4.96, -3.04]		•		
Figueras et al.	12	12.75	65	15.5	12.25	58	6.9%	-3.50 [-7.92, 0.92]				
Grendar et al.	17.4	11.6	48	14	5.4	50	8.6%	3.40 [-0.21, 7.01]		-		
Keck et al.	15	33.8	171	16	21	149	4.5%	-1.00 [-7.09, 5.09]		-		
Topal et al.	19	1.83	162	18	1.83	167	16.9%	1.00 [0.60, 1.40]		•		
Wellner et al.	15	32	59	17	12.5	57	2.5%	-2.00 [-10.79, 6.79]				
Yeo et al.	17.1	1.6	73	17.7	1.5	72	16.8%	-0.60 [-1.10, -0.10]		1		
Total (95% CI)			826			803	100.0%	-0.74 [-2.24, 0.76]		•		
Heterogeneity: Tau ² = 3	8.43; Chi ^a	² = 105.9	57, df=	9 (P < (0.00001); I z = 9	1%		-100	-50 0	50 100	H
Test for overall effect: Z	= 0.97 (P = 0.33	3)						-100	Favours [PG] Favours		J

Figure 19. Length of hospital stay.